Home › Companies › IMMUNOVANT INC. › 2023-2024

IMMUNOVANT INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and IMMUNOVANT INC.’s Form 8-K, filed 2023-08-23 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
157Asset managers
1,031Fund votes
2023-08-21Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IMMUNOVANT INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by IMMUNOVANT INC.

These tallies are IMMUNOVANT INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2023-08-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IMMUNOVANT INC. — official shareholder meeting results, meeting held 2023-08-21
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Peter Salzmann, M.D., M.B.A.	98,532,525	--	--	17,698,285	4,982,266	Majority: yes
Elect Director: Douglas Hughes	96,590,902	--	--	19,639,908	4,982,266	Majority: yes
Elect Director: George Migausky	96,550,901	--	--	19,679,909	4,982,266	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the ye	121,206,460	5,261	1,355	--	--	Majority: yes

Source: IMMUNOVANT INC., Form 8-K, filed with the SEC on 2023-08-23 — read the filing on EDGAR.

How asset managers voted at the IMMUNOVANT INC. 2023-2024 meeting

Each item below shows how the 157 asset managers that disclosed a IMMUNOVANT INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of IMMUNOVANT INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

97% fund support · no official result

FOR 97%

The 152 asset managers below cast 97% of the shares they voted on this item FOR (48,714,023 for, 1,316,710 against).

FOR: 48,714,023 (97.4%)AGAINST: 1,316,710 (2.6%)ABSTAIN: 8,900 (0.0%)

Largest asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of our named executive officers.” at IMMUNOVANT INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	9,093,977	0	For
Deep Track Capital, LP	5,688,800	0	For
Vanguard	5,240,167	0	For
State Street	5,130,778	0	For
BlackRock	3,156,498	0	For
Avidity Partners Management LP	2,155,078	0	For
Logos Global Management LP	2,050,000	0	For
Redmile Group, LLC	1,728,313	0	For
PERCEPTIVE ADVISORS LLC	1,367,104	0	For
Victory Capital	1,226,236	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,100,117	0	For
COMMODORE CAPITAL LP	900,000	0	For
Charles Schwab	783,104	0	For
Dimensional	772,849	0	For
Point72	745,938	0	For
Two Sigma	569,031	0	For
Woodline Partners LP	568,615	0	For
Nuveen	0	562,883	Against
TIAA	0	562,500	Against
PICTET ASSET MANAGEMENT SA	500,358	0	For
JPMorgan	425,432	0	For
PFM Health Sciences, LP	394,538	0	For
Aberdeen	336,200	0	For
PLATINUM INVESTMENT MANAGEMENT LTD	328,842	0	For
Cormorant Asset Management, LP	268,759	0	For

Showing the 25 largest of 152 asset managers. See all 152 in the interactive database.

2. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Douglas Hughes

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%

FOR: 96,590,902WITHHELD: 19,639,908

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Douglas Hughes”): 96,590,902 for, 19,639,908 withheld, per its Form 8-K filed 2023-08-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 130,565,429 outstanding shares: 74% for, 15% withheld (89% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (6,093,893 for, 0 against).

FOR 36%ABSTAIN 64%

FOR: 6,093,893 (36.3%)ABSTAIN: 10,682,985 (63.7%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,134,554	23,200	For
Fidelity	0	3,969,673	Abstain
State Street	0	2,136,788	Abstain
BlackRock	0	1,552,132	Abstain
TIAA	0	562,500	Abstain
Dimensional	0	557,922	Abstain
Victory Capital	0	452,381	Abstain
Charles Schwab	391,552	0	For
Aberdeen	336,200	0	For
JPMorgan	0	319,087	Abstain
Bridge Builder Trust	0	174,411	Abstain
Equitable	0	138,437	Abstain
EA Series Trust	136,057	0	For
Prudential/PGIM	50,550	60,690	Abstain
ALPS ETF Trust	0	95,187	Abstain
Lincoln Financial	0	94,888	Abstain
Direxion Shares ETF Trust	0	75,983	Abstain
ProShares	0	60,139	Abstain
Jackson National	0	54,732	Abstain
Voya	0	53,677	Abstain
QUANTITATIVE MASTER SERIES LLC	0	48,012	Abstain
Federated Hermes	34,649	0	For
Northern Trust	0	29,600	Abstain
New York Life	0	26,616	Abstain
Brighthouse	0	25,365	Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

3. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: George Migausky

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD 17%

FOR: 96,550,901WITHHELD: 19,679,909

IMMUNOVANT INC.’s own tally for this item (“Elect Director: George Migausky”): 96,550,901 for, 19,679,909 withheld, per its Form 8-K filed 2023-08-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 130,565,429 outstanding shares: 74% for, 15% withheld (89% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (6,096,369 for, 0 against).

FOR 36%ABSTAIN 64%

FOR: 6,096,369 (36.3%)ABSTAIN: 10,680,509 (63.7%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	5,134,554	23,200	For
Fidelity	0	3,969,673	Abstain
State Street	0	2,136,788	Abstain
BlackRock	0	1,552,132	Abstain
TIAA	0	562,500	Abstain
Dimensional	0	557,922	Abstain
Victory Capital	0	452,381	Abstain
Charles Schwab	391,552	0	For
Aberdeen	336,200	0	For
JPMorgan	0	319,087	Abstain
Bridge Builder Trust	0	174,411	Abstain
Equitable	0	138,437	Abstain
EA Series Trust	136,057	0	For
Prudential/PGIM	50,550	60,690	Abstain
ALPS ETF Trust	0	95,187	Abstain
Lincoln Financial	0	94,888	Abstain
Direxion Shares ETF Trust	0	75,983	Abstain
ProShares	0	60,139	Abstain
Jackson National	0	54,732	Abstain
Voya	0	53,677	Abstain
QUANTITATIVE MASTER SERIES LLC	0	48,012	Abstain
Federated Hermes	34,649	0	For
Northern Trust	0	29,600	Abstain
New York Life	0	26,616	Abstain
Brighthouse	0	25,365	Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

4. To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2024 Annual Meeting of Stockholders and until the successors are duly elected and qualified: Nominees: Peter Salzmann, M.D., M.B.A.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 98,532,525WITHHELD: 17,698,285

IMMUNOVANT INC.’s own tally for this item (“Elect Director: Peter Salzmann, M.D., M.B.A.”): 98,532,525 for, 17,698,285 withheld, per its Form 8-K filed 2023-08-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 130,565,429 outstanding shares: 75% for, 14% withheld (89% of the company cast a for/withheld vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (5,533,184 for, 0 against).

FOR 33%ABSTAIN 67%

FOR: 5,533,184 (33.0%)ABSTAIN: 11,243,694 (67.0%)

Largest asset managers voting on “To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our” at IMMUNOVANT INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	0	5,157,754	Abstain
Fidelity	27,067	3,942,606	Abstain
State Street	2,136,788	0	For
BlackRock	1,552,132	0	For
TIAA	562,500	0	For
Dimensional	0	557,922	Abstain
Victory Capital	0	452,381	Abstain
Charles Schwab	391,552	0	For
Aberdeen	336,200	0	For
JPMorgan	0	319,087	Abstain
Bridge Builder Trust	18,967	155,444	Abstain
Equitable	138,437	0	For
EA Series Trust	136,057	0	For
Prudential/PGIM	50,550	60,690	Abstain
ALPS ETF Trust	0	95,187	Abstain
Lincoln Financial	37,000	57,888	Abstain
Direxion Shares ETF Trust	0	75,983	Abstain
ProShares	0	60,139	Abstain
Jackson National	0	54,732	Abstain
Voya	0	53,677	Abstain
QUANTITATIVE MASTER SERIES LLC	48,012	0	For
Federated Hermes	34,649	0	For
Northern Trust	29,600	0	For
New York Life	0	26,616	Abstain
Brighthouse	0	25,365	Abstain

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

5. To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31,2024.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 121,206,460AGAINST: 5,261

IMMUNOVANT INC.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent regi”): 121,206,460 for, 5,261 against, per its Form 8-K filed 2023-08-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 130,565,429 outstanding shares: 93% for, 0.1% against (93% of the company cast a for/against vote).

The 49 asset managers below cast 100% of the shares they voted on this item FOR (16,776,878 for, 0 against).

FOR 100%

FOR: 16,776,878 (100.0%)

Largest asset managers voting on “To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independe” at IMMUNOVANT INC., 2023-2024
Asset manager	For	Vote
Vanguard	5,157,754	For
Fidelity	3,969,673	For
State Street	2,136,788	For
BlackRock	1,552,132	For
TIAA	562,500	For
Dimensional	557,922	For
Victory Capital	452,381	For
Charles Schwab	391,552	For
Aberdeen	336,200	For
JPMorgan	319,087	For
Bridge Builder Trust	174,411	For
Equitable	138,437	For
EA Series Trust	136,057	For
Prudential/PGIM	111,240	For
ALPS ETF Trust	95,187	For
Lincoln Financial	94,888	For
Direxion Shares ETF Trust	75,983	For
ProShares	60,139	For
Jackson National	54,732	For
Voya	53,677	For
QUANTITATIVE MASTER SERIES LLC	48,012	For
Federated Hermes	34,649	For
Northern Trust	29,600	For
New York Life	26,616	For
Brighthouse	25,365	For

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

99.7% fund support · no official result

FOR 99.7%

The 3 asset managers below cast 99.7% of the shares they voted on this item FOR (337,841 for, 872 against).

FOR: 337,841 (99.7%)AGAINST: 872 (0.3%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at IMMUNOVANT INC., 2023-2024
Asset manager	For	Against	Vote
JPMorgan	322,992	0	For
ALGERT GLOBAL LLC	14,849	0	For
Desjardins Global Asset Management Inc.	0	872	Against

Largest IMMUNOVANT INC. shareholders voting in 2023-2024

Ranked by the number of IMMUNOVANT INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 130,565,429 shares outstanding at the time of that meeting.

Top IMMUNOVANT INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Fidelity	6.97%
2	Deep Track Capital, LP	4.36%
3	Vanguard	4.01%
4	State Street	3.93%
5	BlackRock	2.42%
6	Avidity Partners Management LP	1.65%
7	Logos Global Management LP	1.57%
8	Redmile Group, LLC	1.32%
9	PERCEPTIVE ADVISORS LLC	1.05%
10	Victory Capital	0.94%

Reported IMMUNOVANT INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

IMMUNOVANT INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Roivant Sciences Ltd.	61.13%	DEF14A
FMR (Fidelity)	11.28%	13F
FMR LLC	6.03%	DEF14A
Vanguard Group	5.23%	13F
BlackRock	4.39%	13F
State Street	2.79%	13F
Peter Salzmann, M.D., M.B.A.	2.42%	DEF14A
Morgan Stanley	1.50%	13F
T. Rowe Price	1.43%	13F
Goldman Sachs	1.14%	13F

Percentages above are of 130,565,429 shares outstanding, as reported by IMMUNOVANT INC. on its Form 10-Q dated 2023-06-30 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IMMUNOVANT INC.’s 10-Q dated 2023-06-30. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At IMMUNOVANT INC.'s shareholder meeting held 2023-08-21, in the 2023-2024 proxy season, 157 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,031 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. IMMUNOVANT INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — the reporting funds cast 97% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

IMMUNOVANT INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.